Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. - Wikidata - wikimedia - TriplyDB

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

http://www.wikidata.org/entity/Q34309214

about

Targeting DNA Replication Stress for Cancer Therapy Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Targeting the Checkpoint to Kill Cancer Cells Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Effects of Chk1 inhibition on the temporal duration of radiation-induced G2 arrest in HeLa cells.HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Targeting lung cancer through inhibition of checkpoint kinases.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Targeting cell cycle regulators in hematologic malignancies.Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.Rational Combinations of Targeted Agents in AML Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736 Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.A knockout screen for protein kinases required for the proper meiotic segregation of chromosomes in the fission yeast Schizosaccharomyces pombe.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.Expression and clinical significance of Wee1 in colorectal cancer.Cell Cycle Regulation and Melanoma.Targeting the ATR-CHK1 Axis in Cancer Therapy A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells---Cdc2 activity is up-regulated by targeting WEE1.Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability.Upgrading gemcitabine with recycled kinase inhibitors MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.Short-circuiting the cell cycle for cancer therapy.Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.ATR/CHK1 inhibitors and cancer therapy.

P2860

Q26739923-EED6A37C-1B88-4B7F-949A-67872C36C96C Q26745686-9795B621-4F7A-4415-8E73-5C3A22C618D4 Q26795781-495A68E3-A404-49EB-885C-B3993DEC9857 Q26864870-F5E0C554-6D80-4C65-A1AD-179D3CBDE077 Q34287982-BB959863-231D-441B-B571-37EF0E239396 Q34366587-223D2321-D3AC-4ABE-9B2C-047E9ABEFBF9 Q34404877-B60A47B4-7199-4F17-96D2-51492509D41D Q34544769-D2DDC3BE-5AAA-47A5-9A74-0C7415178478 Q34808616-F653F1F0-88B7-45FA-AAE0-B6676AD6979C Q35128547-CC25EBBC-84DA-4856-AEDE-02C813D0F596 Q35287823-9B06F01B-CB94-4CE2-87B8-7E0857754671 Q35334436-60BA1FBB-1E75-4A9B-B902-317C4E8BB4BF Q35550255-4A19DD9E-9073-4447-B51E-B02AC7C7290F Q35657004-1C9A78B6-88B6-488A-8610-7E5CD4EB81A8 Q35750491-660BCE58-64B2-413E-B386-A409FDA577A5 Q36244669-B69C4A9D-DF2F-44FE-AD49-7336534B1878 Q36356243-90F6E398-B016-4343-8722-910B6A9EA85B Q36454659-86B6FB05-3B71-4A86-BFE6-68EC0B6E6964 Q36545701-054F047F-AE0D-4646-97BF-59A37F4560AC Q36546455-20DDEBA9-6EB1-4BE5-84E4-022D6562E689 Q36674339-2028BDBB-BEE4-4353-95C3-9DE1E75AB375 Q36738836-D7B06476-DEE6-4019-A6E4-B20A291D8187 Q36843733-CCC0B194-5AFE-4674-9E56-C1FC569EB3B8 Q37676283-9114ACB9-3478-424A-A05E-B652BD6B6A2B Q37706861-268A4E63-C51D-4986-AD86-B2E43C5FAA1A Q38737092-8F112EAB-36BC-4EDF-89A0-BEB803053A04 Q38815527-55E28E3D-7B92-4480-B7E1-1D4E5E8CB451 Q38817102-9F08CDB7-7AAB-427F-A036-782CE2156372 Q38838357-B794C3D8-6B25-4BB7-A4FA-CE899F82E9BC Q38948573-A8A67C9B-FD1B-4747-A3FE-5A9DD7A35518 Q39020753-8E939FD0-69A6-41E7-BABF-E19B8B384312 Q39137856-856EA752-1741-41D9-8BA5-06F63D0A23BE Q40483960-409045E1-1670-4F83-ACE5-141BC608C015 Q41618744-1E88DE5F-DF59-459A-BFFB-6838F8F005D2 Q41979272-AF9C0090-2EB9-4446-984C-BCED25297DC8 Q42317541-81BAA75A-062A-4766-ABCD-A9395B1BAA98 Q43084851-C7FCD2E7-4FA2-4757-A4E3-4B6383325A3A Q43241497-73C81AA5-28C7-4CA7-802E-2DC4C06F35F8 Q47122646-21C9FBFC-C082-4602-B3DF-AA649CD57A9D Q47622968-BFC79622-DDEA-4C5B-B162-3B1FD7EA0413

P2860

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

http://www.wikidata.org/entity/Q34309214

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@ast

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@en

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@nl

type

label

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@ast

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@en

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@nl

prefLabel

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@ast

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@en

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@nl

P1433

Q34309214-2637CC30-80D6-4C88-A714-4380B1FBEF1B

P1476

Q34309214-F80275E1-87BA-49B5-B7F4-060A2ECAECEE

P2093

Q34309214-046BAF39-06F4-46B9-A2AB-A0255F5D4AD9

Q34309214-49DE50D6-2ED9-4D1C-8293-6E51639511E5

Q34309214-6C7C750B-F3E0-45DB-B7FD-06A024F9333D

Q34309214-ABEC5ECC-91B0-44AF-BBFA-A8E4F59031DE

Q34309214-CA032ECA-1444-4DE7-A293-DEB9AF0055BC

Q34309214-D667717B-0577-40E5-BF50-82B94AEA11FF

Q34309214-EE910124-217C-440C-94F7-797F20E19040

Q34309214-F4A32F8E-8B20-486B-B37D-8A8A2E16A28B

P2860

Q34309214-05531AB0-99BE-4E08-A040-5AF5C9E34B7D

Q34309214-05FBFA2B-7453-4CF7-B440-2809B08DB2B0

Q34309214-0CEE7B6B-F845-47DB-B34B-D0D52BC27123

Q34309214-0E81A222-94FB-495E-AF9A-7728D0841E13

Q34309214-1400F7DB-7933-46E5-9011-F6DAF0805718

Q34309214-1BD27A38-48C8-4F91-B5F1-05578920136F

Q34309214-1D6CBE7D-5DAB-4FE9-AE40-7030AE77C71B

Q34309214-2AA85B70-1655-4FEE-B090-E452480183FB

Q34309214-42C9DCEA-970E-4712-9C53-FF1E3072E274

Q34309214-436396B6-7E20-45C6-B1E4-B777DDD3934F

P304

Q34309214-E2975889-B00D-4189-BBF8-218622CD6A38

P31

Q34309214-C76319CD-42A1-40BE-AE3B-43CA7545AB42

P356

Q34309214-87267B5D-2594-499C-9503-7B882FD504C2

P433

Q34309214-D0CC944E-0B2E-46FC-AD5B-544ED5FD8F0D

P478

Q34309214-A3A35EBD-F2A4-48F5-9C12-7E2509A0D3A1

P577

Q34309214-50E16F2B-E986-41D9-A92E-2B3C33A33A63

P698

Q34309214-2FBEB263-7027-4125-A656-657563C23CA4

P356

P1433

P1476

Combined inhibition of Chk1 an ...... mor growth inhibition in vivo.

@en

P2093

Cinzia Celenza

http://www.w3.org/2001/XMLSchema#string

Francesca Ricci

http://www.w3.org/2001/XMLSchema#string

Giovanna Damia

http://www.w3.org/2001/XMLSchema#string

Laura Carrassa

http://www.w3.org/2001/XMLSchema#string

Marco Mazzoletti

http://www.w3.org/2001/XMLSchema#string

Massimo Broggini

http://www.w3.org/2001/XMLSchema#string

Monica Lupi

http://www.w3.org/2001/XMLSchema#string

Rosaria Chilà

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA damage response: putting checkpoints in perspective

Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216

The concept of synthetic lethality in the context of anticancer therapy

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division

The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis.

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.

Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation.

Positive regulation of Wee1 by Chk1 and 14-3-3 proteins.

P304

2507-2517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.20899

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22713237

http://www.w3.org/2001/XMLSchema#string